Abstract 200P
Background
Transarterial chemoembolization (TACE) is the first-line treatment for intermediate-stage Hepatocellular carcinoma (HCC) patients. However, predicting the Survival of hepatocellular carcinoma (HCC) patients receiving TACE remains challenging.
Methods
This retrospective study included 1805 HCC patients receiving TACE. Each patient was randomized to a training set (n = 1264) and a validation set (n = 541). We investigated prognostic factors in the training set and developed an easily applicable ALFP (ALBI grade, AFP, and Prothrombin time) score, which was evaluated in the validation set.
Results
We built the ALFP score using baseline ALBI grade 2 or 3 (HR 1.301, 95% CI 1.073-1.577,p = 0.007) and AFP ≥ 100 ng/ml (HR 1.328, 95% CI 1.133-1.557, p < 0.001)and PT 13.1 s (HR 1.262, 95% CI 1.047-1.521, p=0.015), which were identified as unfavorable prognosis factors in a multivariate analysis. The median OS in patients with ALFP scores of 0, 1, 2, and 3 points was 50.1 months (95% CI NA), 33.6months (95% CI 27.4–39.8), and 20.4months (95% CI 18.0–22.8), and 12.7 months (95% CI 10.2–15.2), respectively; the difference was statistically significant (p < 0.001).the result were confirmed in the validation set(The median OS ,0/1/2/3 points = 42.5/32.6/20.4 /13.0 months, p < 0.0019).
Conclusions
The ALFP score can predict the prognosis of HCC patients receiving TACE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiong Chen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract